Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients.
Mariani S, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Donisi C, Persano M, Pinna G, Cimbro E, Parrino A, Spanu D, Pretta A, Lai E, Liscia N, Lupi A, Giglio E, Palomba G, Casula M, Pisano M, Palmieri G, Scartozzi M. Mariani S, et al. Among authors: liscia n. Front Oncol. 2022 Apr 21;12:852583. doi: 10.3389/fonc.2022.852583. eCollection 2022. Front Oncol. 2022. PMID: 35530345 Free PMC article.
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.
Ziranu P, Lai E, Schirripa M, Puzzoni M, Persano M, Pretta A, Munari G, Liscia N, Pusceddu V, Loupakis F, Demurtas L, Libertini M, Mariani S, Migliari M, Dubois M, Giampieri R, Sotgiu G, Dei Tos AP, Lonardi S, Zaniboni A, Fassan M, Scartozzi M. Ziranu P, et al. Among authors: liscia n. Target Oncol. 2021 Jul;16(4):517-527. doi: 10.1007/s11523-021-00816-3. Epub 2021 May 10. Target Oncol. 2021. PMID: 33970400 Free PMC article.
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients.
Puzzoni M, Ziranu P, Demurtas L, Lai E, Mariani S, Liscia N, Soro P, Pretta A, Impera V, Camera S, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Scartozzi M. Puzzoni M, et al. Among authors: liscia n. Future Oncol. 2020 Jan;16(2):4337-4339. doi: 10.2217/fon-2019-0624. Epub 2019 Dec 3. Future Oncol. 2020. PMID: 31793396 Free article. No abstract available.
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.
Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Lai E, et al. Among authors: liscia n. Cancers (Basel). 2020 May 13;12(5):1214. doi: 10.3390/cancers12051214. Cancers (Basel). 2020. PMID: 32413973 Free PMC article. Review.
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu A, Saba G, Camera S, Musio F, Puzzoni M, Pusceddu V, Madeddu C, Casadei Gardini A, Scartozzi M. Lai E, et al. Among authors: liscia n. Crit Rev Oncol Hematol. 2021 Jan;157:103167. doi: 10.1016/j.critrevonc.2020.103167. Epub 2020 Nov 12. Crit Rev Oncol Hematol. 2021. PMID: 33271389 Review.
Immune Checkpoint Inhibitors in the Treatment of HCC.
Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Donisi C, et al. Among authors: liscia n. Front Oncol. 2021 Jan 7;10:601240. doi: 10.3389/fonc.2020.601240. eCollection 2020. Front Oncol. 2021. PMID: 33585218 Free PMC article. Review.
Molecular-driven treatment for biliary tract cancer: the promising turning point.
Persano M, Puzzoni M, Ziranu P, Pusceddu V, Lai E, Pretta A, Donisi C, Pinna G, Spanu D, Cimbro E, Parrino A, Liscia N, Mariani S, Dubois M, Migliari M, Scartozzi M. Persano M, et al. Among authors: liscia n. Expert Rev Anticancer Ther. 2021 Nov;21(11):1253-1264. doi: 10.1080/14737140.2021.1982699. Epub 2021 Sep 24. Expert Rev Anticancer Ther. 2021. PMID: 34551663 Review.
Uncovering key targets of success for immunotherapy in pancreatic cancer.
Pretta A, Lai E, Persano M, Donisi C, Pinna G, Cimbro E, Parrino A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Pusceddu V, Puzzoni M, Ziranu P, Scartozzi M. Pretta A, et al. Among authors: liscia n. Expert Opin Ther Targets. 2021 Nov;25(11):987-1005. doi: 10.1080/14728222.2021.2010044. Epub 2021 Dec 13. Expert Opin Ther Targets. 2021. PMID: 34806517
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study.
Lai E, Puzzoni M, Ziranu P, Cremolini C, Lonardi S, Banzi M, Mariani S, Liscia N, Cinieri S, Dettori M, Mencoboni M, Nappo F, Piacentini G, Labianca R, Zucchelli G, Boccaccino A, Conca V, Pusceddu V, Zaniboni A, Scartozzi M; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente, Italian Group for the Study of Gastrointestinal Tumors). Lai E, et al. Among authors: liscia n. Clin Colorectal Cancer. 2021 Dec;20(4):e253-e262. doi: 10.1016/j.clcc.2021.07.008. Epub 2021 Jul 31. Clin Colorectal Cancer. 2021. PMID: 34429245
26 results